BioPharma Credit - The silent yield specialist in the life science sector
Scores at time of recommendation (January 24, 2026)
5-year stock timeline
26 Oct 2021
Reported a 7.3% NAV total return (annualised) over the three-year period. [1] Positioned BPCR as a steady, income-focused specialist creditor to life sciences, marketed as a reliable yield and total-return vehicle. Trading as a range-bound income trust with limited momentum; investor focus remained on yield rather than growth.
10 Jan 2022
Announced entry into new senior secured loan agreements. [1] Viewed as active deployment of capital into secured life-sciences lending, supporting the income story and distribution coverage. Modest uptrend as news underpinned yield expectations.
16 Mar 2022
Entered a new senior secured loan agreement for up to US$50m. [1] Signalled scale of deployment capability and underwriting appetite, reinforcing investor confidence in repeatable deal flow. Period of renewed accumulation and bounce off prior ranges.
3 Nov 2022
Company commentary indicated it was on track to deliver a strong—possibly record—annual NAV total return. [1] Market perception shifted briefly toward outperformance versus peers on NAV metrics, reaffirming the income plus NAV upside story. Short rally around NAV-outperformance messaging.
31 Dec 2023
Published Final Results and Annual Report for year ended 31 Dec 2023. [9][11] Earnings showed variability with lower EPS in 2023 versus 2022, reminding investors of earnings volatility tied to portfolio realised and unrealised items; the mandate remained income-oriented rather than pure growth. [10] Period marked by correction and range trading with episodic drawdowns as earnings volatility was digested.
Mar 2024
Investor update reaffirmed strategy and targeted an annual dividend of 7 US cents per share. [14] Reiteration of a predictable income objective helped reframe BPCR as a reliable distributer of yield to income investors. Stabilisation within a trading range as the distribution target provided a valuation anchor.
7 Feb 2025
RNS statement regarding LumiraDx highlighted single-asset and counterparty risk within parts of the portfolio, driving investor scrutiny on asset-level credit risk and recoverability. [7] Short-term volatility and drawdown around asset-specific news.
6 May 2025
RNS update on investments disclosed portfolio activity. [6] Management signalled active portfolio management through realisation and reinvestment; investors interpreted this as prudent credit management amid market uncertainty. Choppy price action as the market re-priced exposures.
30 May 2025
RNS further update on the investment portfolio disclosed portfolio composition and positions. [5] Increased transparency on exposures reduced uncertainty for some investors, supporting a tactical re-rating for those focused on credit quality. Range trading with occasional positive bursts on clarity releases.
29 Aug 2025
RNS transaction in Own Shares (correction issued to prior disclosure regarding buybacks and own-share transactions). [4] Buyback activity signalled management willingness to use cash and capital return mechanisms, interpreted by many as management viewing the stock as undervalued. Technical support forming as buyback activity acted as a floor under the share price.
24 Sep 2025
Half-year report (H1) published. [8] H1 disclosure continued emphasis on income generation and portfolio credit monitoring; investors remained focused on yield sustainability. Continued range trading with no decisive breakout.
31 Dec 2025
Year-end financial highlights posted: share price $0.9160; NAV per share $1.0192; discount to NAV 10.1%; net assets $1,150.9m; ordinary shares in issue 1,129.2m; shares in treasury 244.7m. [2] Persistent mid-single to low-double-digit discount to NAV; market viewed BPCR as a yield play trading at an NAV discount but supported by buyback and treasury activity and targeted distributions. [2] Drawdown versus NAV but stabilising—range with discount compression potential.
9 Jun 2026
Announced a new senior secured loan agreement with Idorsia Pharmaceuticals Ltd. [3] Continued evidence of deal flow into secured life-sciences lending, regarded positively by income-focused shareholders as accretive to yield and portfolio diversification. [3] Short-term positive reaction and micro-rally on deployment news.
11 Jul 2026
Share price at 0.96 implies a narrower discount versus reported NAV per share of $1.0192 (31 Dec 2025), reflecting discount compression and marginally improved sentiment versus end-2025 levels; market treating BPCR increasingly as a distribution-focused value proposition combining price recovery and continued deal flow. [2] Short-term recovery and rally with discount compression versus late-2025; technical posture more constructive than the 2024–2025 corrective range.
Key Points
- Specialized lender for biotech and pharmaceutical companies with secured loans
- Dividend yield of 7.78% with share price close to 52-week low (USD 0.79-0.96)
- Impressive margins: 86.9% operating margin, 79.6% profit margin
- Equity ratio above 98% signals solid balance sheet structure
- Next dividend (USD 0.02) with ex-day 2. February 2026
Investment Thesis
BioPharma Credit occupies a niche in the life science sector that is often overlooked: The company grants collateralized loans to established biotech and pharmaceutical companies and benefits from the structural growth of the sector. Demographic change and rising healthcare expenditure ensure a continuous need for financing, while the business model focuses on companies with products that have already been approved or are about to be approved - which significantly reduces the risk profile compared to pure biotech bets. The combination of an attractive dividend yield, robust margins and defensive positioning makes BioPharma Credit an interesting option for income-oriented investors.
Key risks and downside factors
BioPharma Credit PLC (BPCR.LSE) is a UK-listed investment trust supplying royalty-backed loans and structured credit to biopharma companies. Its competitive set spans both public peers—Royalty Pharma (RPRX, ISIN GB00BMVP7Y09), XOMA Royalty (XOMA, ISIN US98419J2069) and DRI Healthcare Trust (DHT.UN, ISIN CA23344H1091)—and private specialists like HealthCare Royalty Partners, Oberland Capital and NovaQuest. The portfolio's risk surface is multifaceted. Clinical and commercial outcomes of underlying borrowers matter most, but concentration risk and single-asset exposure create structural vulnerability. Refinancing and illiquidity pressures can emerge quickly in stressed credit environments. Currency movements, interest-rate shifts and credit-spread widening all move the needle on valuations and returns. [Royalty Pharma investor disclosures; MarketScreener / company filings; TSX listings and industry presentations.]
- Credit risk is materially dependent on clinical trial outcomes, regulatory approvals, and commercial viability of specific drug assets. Repayment capacity hinges on these execution risks rather than stable cash flows.
- Concentrated royalty exposure creates outsized NAV swings. When a few streams dominate the portfolio, a single underperforming asset doesn't just dent returns—it can materially reshape the fund's value [1].
- Liquidity and refinancing risk present a structural challenge for royalty and credit positions. These assets are inherently illiquid, typically long-dated, and operate within a thin secondary market—creating genuine uncertainty around both exit timing and the terms available when refinancing becomes necessary.
- Rising interest rates and widening credit spreads compress the fair value of fixed-income and royalty assets, while GBP/USD currency mismatches can weigh on reported NAV and distributions.
Competitive landscape
BioPharma Credit (BPCR) is a London-listed specialist lender financing life-sciences companies through debt and royalty-backed structures. The firm targets predictable income streams from approved products' cash flows. It competes against larger dedicated royalty buyers and hybrid acquirers pursuing the same late-stage, revenue-generating assets. The business carries meaningful risks: portfolio concentration tied to product sales performance, credit and liquidity exposure with refinancing dependencies, and yield compression from better-capitalized competitors and tighter funding conditions.
| Company | Ticker |
|---|---|
| Royalty Pharma plc | RPRX.NASDAQ |
| Ligand Pharmaceuticals Incorporated | LGND.NASDAQ |
Private competitors
- HealthCare Royalty Partners (HCRx)
- RTW Investments
- Oberland Capital
- XOMA Royalty
- Sagard Healthcare Partners
Get More Stock Analyses Like This
Receive hand-picked stock recommendations with detailed analyses every week
Start Free TrialCatalysts
- Upcoming dividend payment on 27. February 2026 (ex-day 2. February)
- Further growth in the life science lending business through new financing rounds
- Possible portfolio expansion with increasing demand for biotech financing
- Stabilization of the share price after reaching the 52-week low
Analysis
Performance Figures of BioPharma Credit PLC
Relative Performance vs Benchmarks
| Period | BioPharma Credit PLC | vs DAX | vs S&P 500 (SPY) |
|---|---|---|---|
| 1M | +3.58% | +3.56% | +2.72% |
| 3M | +6.01% | +5.15% | -0.55% |
| 6M | +12.98% | +14.49% | +3.27% |
| 1Y | +21.14% | +17.37% | -1.12% |
| 3Y | +56.15% | +1.09% | -17.64% |
| 5Y | +76.41% | +16.08% | -10.83% |
Get More Stock Analyses Like This
Receive hand-picked stock recommendations with detailed analyses every week
Start Free TrialHistorical valuation trends
How the company’s key valuation ratios (P/E, P/S, P/B and P/CF) have evolved over time compared to today.
| Period | P/E Ratio | P/S Ratio | P/B Ratio | P/CF Ratio |
|---|---|---|---|---|
| Current | 8.3 | 7.7 | 0.9 | 11.9 |
| 1Y ago | 8.2 | 8.3 | 0.9 | 10.3 |
| 3Y ago | 4.2 | 3.5 | 0.9 | 19.1 |
| 5Y ago | 10.1 | 9.3 | 1.0 | 15.7 |
Frequently Asked Questions
Is BioPharma Credit PLC a good investment?
What does BioPharma Credit PLC do?
What are the key metrics for BPCR.LSE?
How has BioPharma Credit PLC's stock price performed?
How is BPCR.LSE valued?
What are the growth catalysts for BioPharma Credit PLC?
- Upcoming dividend payment on 27. February 2026 (ex-day 2. February)
- Further growth in the life science lending business through new financing rounds
- Possible portfolio expansion with increasing demand for biotech financing
- Stabilization of the share price after reaching the 52-week low
What are the key risks when investing in BPCR.LSE?
- Credit risk is materially dependent on clinical trial outcomes, regulatory approvals, and commercial viability of specific drug assets. Repayment capacity hinges on these execution risks rather than stable cash flows.
- Concentrated royalty exposure creates outsized NAV swings. When a few streams dominate the portfolio, a single underperforming asset doesn't just dent returns—it can materially reshape the fund's value [1].
- Liquidity and refinancing risk present a structural challenge for royalty and credit positions. These assets are inherently illiquid, typically long-dated, and operate within a thin secondary market—creating genuine uncertainty around both exit timing and the terms available when refinancing becomes necessary.
- Rising interest rates and widening credit spreads compress the fair value of fixed-income and royalty assets, while GBP/USD currency mismatches can weigh on reported NAV and distributions.
Who are the main competitors of BioPharma Credit PLC?
- Royalty Pharma plc (RPRX.NASDAQ)
- Ligand Pharmaceuticals Incorporated (LGND.NASDAQ)
Key Metrics
Valuation Metrics
Profitability Metrics
Growth Metrics
Dividend history
Long-term record of paid dividends (amount per share and dividend yield at the time of payment).
| Year | Dividend | Yield at payment | Avg. yield |
|---|---|---|---|
| 2026 | 0.02 GBP | 2.42% | 3.51% |
| 2026 | 0.02 GBP | 2.51% | |
| 2026 | 0.03 GBP | 4.45% | |
| 2025 | 0.03 GBP | 4.78% | |
| 2025 | 0.02 GBP | 2.66% | |
| 2025 | 0.02 GBP | 2.57% | |
| 2025 | 0.03 GBP | 4.23% | |
| 2024 | 0.04 GBP | 5.56% | |
| 2024 | 0.02 GBP | 2.56% | |
| 2024 | 0.02 GBP | 2.47% | |
| 2024 | 0.03 GBP | 4.00% | |
| 2023 | 0.04 GBP | 5.45% | |
| 2023 | 0.02 GBP | 2.58% | |
| 2023 | 0.02 GBP | 2.26% | |
| 2023 | 0.03 GBP | 4.21% |
Earnings history & estimates
Historical earnings performance shows how consistently the company meets or exceeds analyst expectations. Forward estimates provide insight into expected profitability and growth trajectory.
Analyst estimates for upcoming periods
Key financial figures
Selected income statement, balance sheet and cash flow figures. Annual and quarterly, based on reported IFRS/GAAP financials.
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | 140.23M | 124.46M | 159.68M | 184.25M | 87.97M |
| Operating income (EBIT) | 129.85M | 122.18M | 108.45M | 182.31M | 84.96M |
| Net income | 129.89M | 122.18M | 108.45M | 182.31M | 84.96M |
| Free cash flow | 91.09M | 111.91M | 123.18M | 184.28M | 96.44M |
| Total assets | 1.17B | 1.20B | 1.36B | 1.36B | 1.37B |
| Equity | 1.15B | 1.18B | 1.34B | 1.34B | 1.36B |
| Net debt | -12.59M | -5.62M | -86.20M | -120.53M | -94.71M |
PWP Leeway UG (haftungsbeschränkt)
